Business Description
Cullinan Oncology Inc
NAICS : 541713
SIC : 2834
One Main Street, Suite 520, Cambridge, MA, USA, 02142
Description
Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 152.92 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | -1.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -7.5 | |||||
| 3-Year EPS without NRI Growth Rate | -7.1 | |||||
| 3-Year FCF Growth Rate | 5.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.12 | |||||
| 9-Day RSI | 62.64 | |||||
| 14-Day RSI | 60.13 | |||||
| 6-1 Month Momentum % | 1.29 | |||||
| 12-1 Month Momentum % | -50.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 18.68 | |||||
| Quick Ratio | 18.68 | |||||
| Cash Ratio | 18.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -57 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -17.56 | |||||
| ROA % | -17.08 | |||||
| ROIC % | -75.9 | |||||
| ROC (Joel Greenblatt) % | -13932.1 | |||||
| ROCE % | -22.97 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 4.14 | |||||
| PS Ratio | 33.66 | |||||
| PB Ratio | 1.58 | |||||
| Price-to-Tangible-Book | 1.58 | |||||
| EV-to-EBIT | -3.44 | |||||
| EV-to-EBITDA | -3.44 | |||||
| EV-to-Forward-Revenue | 1.27 | |||||
| EV-to-FCF | -5.49 | |||||
| Price-to-Net-Current-Asset-Value | 2.18 | |||||
| Price-to-Net-Cash | 2.23 | |||||
| Earnings Yield (Greenblatt) % | -29.07 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:CGEM
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -1.79 | ||
| Beta | 0 | ||
| Volatility % | 55.86 | ||
| 14-Day RSI | 60.13 | ||
| 14-Day ATR ($) | 0.769773 | ||
| 20-Day SMA ($) | 14.272 | ||
| 12-1 Month Momentum % | -50.65 | ||
| 52-Week Range ($) | 7.3 - 30.325 | ||
| Shares Outstanding (Mil) | 44.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cullinan Oncology Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||